European Investor
28 Aug 2026, 16:43
Gilead Wins FDA Approval for Bixlenvo, Expanding Its HIV Treatment Portfolio
Gilead Sciences (NASDAQ: GILD) received U.S. FDA approval for Bixlenvo, a new once-daily single-tablet HIV treatment for virologically suppressed adults, including patients currently requiring complex treatment regimens.
Bixlenvo combines bictegravir, an integrase inhibitor with a high barrier to resistance, with lenacapavir, Gilead’s first-in-class capsid inhibitor. Importantly, it becomes the first and only single-tablet regimen for virologically suppressed patients on complex HIV regimens who cannot use currently available single-tablet options.
Approval was supported by the Phase 3 ARTISTRY-1 and ARTISTRY-2 trials. In both studies, Bixlenvo demonstrated comparable efficacy in maintaining viral suppression through Week 48 and was generally well tolerated, with no significant new safety concerns identified.
The approval is strategically important for Gilead because HIV remains one of its core franchises. Bixlenvo adds a differentiated treatment option for patients with resistance, tolerability issues or complicated multi-pill regimens, while extending the commercial potential of lenacapavir beyond its existing uses. It also strengthens Gilead’s broader strategy of developing daily, weekly and longer-acting HIV treatment and prevention options.
Gilead Sciences (NASDAQ: GILD) received U.S. FDA approval for Bixlenvo, a new once-daily single-tablet HIV treatment for virologically suppressed adults, including patients currently requiring complex treatment regimens.
Bixlenvo combines bictegravir, an integrase inhibitor with a high barrier to resistance, with lenacapavir, Gilead’s first-in-class capsid inhibitor. Importantly, it becomes the first and only single-tablet regimen for virologically suppressed patients on complex HIV regimens who cannot use currently available single-tablet options.
Approval was supported by the Phase 3 ARTISTRY-1 and ARTISTRY-2 trials. In both studies, Bixlenvo demonstrated comparable efficacy in maintaining viral suppression through Week 48 and was generally well tolerated, with no significant new safety concerns identified.
The approval is strategically important for Gilead because HIV remains one of its core franchises. Bixlenvo adds a differentiated treatment option for patients with resistance, tolerability issues or complicated multi-pill regimens, while extending the commercial potential of lenacapavir beyond its existing uses. It also strengthens Gilead’s broader strategy of developing daily, weekly and longer-acting HIV treatment and prevention options.
